Company Media
New investor guide profiles biotech companies to watch
27 September 2022
Immuron (ASX:IMC) shifts focus to therapeutic drug candidate
19 August 2022
Immuron (ASX:IMC) tables 494pc increase in North American FY22 Travelan sales
11 July 2022
Immuron (ASX:IMC) enters research agreement with Monash University
15 December 2020
Immuron (ASX:IMC) reveals positive anti-diarrhoea vaccine results
9 November 2020
Immuron (ASX:IMC) takes steps towards FDA approval for stomach bug treatment
12 October 2020
Immuron's stock pulls back but still nearly doubles after stock offering
21 July 2020
Immuron’s commercially available products found to neutralise COVID-19 during in vitro research
21 July 2020
Could Immuron’s (ASX:IMC) traveller’s diarrhoea treatment be used to fight COVID-19?
21 July 2020
Immuron reveals anti-COVID potential, raises $28 million
20 July 2020
Immuron (ASX:IMC) develops research agreement
22 June 2020
Immuron and US Naval Medical Research Center prepare to develop novel oral therapeutic for E-Coli
10 June 2020
Immuron's stock blasts off nearly 10-fold after partner NMRC seeks pre-IND meeting with FDA
9 June 2020
Diarrhea: A major health issue for Americans travelling abroad
12 February 2020
Walter Reid Army Institute of Research 2019 Year in Review
15 January 2020
Immuron partnering with Walter Reid Army Institute of Research to test Travelan against Shigella, ETEC, Vibrio cholerae and Campylobacter jejuni isolates (2020, WRAIR's Investigator's Dispatch)
1 January 2020
Immuron’s shares rise on the back of Travelan® results
12 June 2019
Travelan on The Not Old Better Show with Dr. Hailey Weerts - Research Scientist of Walter Reed Army Institute of Research WRAIR
1 June 2019
Immuron CEO interviewed on the RedChip Money Report, USA
10 October 2018
Immuron and US Department of Defense look to develop silver bullet for gastro infections
16 July 2018